Skip to content

CPB Prime Fluid Strategies to Preserve Mcirocirculatory Perfusion

Optimization of Prime Fluid Strategy to Preserve Microcirculatory Perfusion During Cardiac Surgery With Cardiopulmonary Bypass

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05647057
Acronym
PRIME
Enrollment
48
Registered
2022-12-12
Start date
2023-07-10
Completion date
2024-08-08
Last updated
2025-03-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endothelial Dysfunction, Fluid Overload, Hemolysis

Keywords

Microcirculation, Cardiopulmonary bypass, Colloid oncotic pressure, Hemodilution, Hemolysis

Brief summary

Acute microcirculatory perfusion disturbances is common in critical illness and associated with higher morbidity and mortality. Recent findings by the investigators' group showed that microcirculatory perfusion is disturbed during cardiac surgery with cardiopulmonary bypass (CPB) and remain disturbed up to 72 (seventy two) hours after surgery. A cardiopulmonary bypass is a machine which takes over heart and lung function, during the procedure. The disturbed microcirculation is associated with organ dysfunction induced by cardiac surgery using CPB, which is frequently seen (up to 42%, forty two percent) and results in a six-fold increase in mortality rate. The underlying cause of disturbed microcirculation is a higher endothelial permeability and vascular leakage and are a consequence of systemic inflammation, hemodilution (dilution of blood), hypothermia and hemolysis (breakdown of red blood cells). To gain the knowledge regarding disturbed microcirculation the investigators previously showed that hemodilution attributes to this disturbed perfusion. Hemodilution lowers colloid oncotic pressure (COP). Also, COP is affected by free hemoglobin, which increases with hemolysis and attributes to a disturbed microcirculation following CPB. This is interesting, as to the best of our knowledge, the effect of minimizing hemodilution and hemolysis during cardiac surgery on the microcirculatory perfusion has never been investigated, but could be the key factor in reducing organ dysfunction.

Detailed description

In this project the investigators focus on reducing microcirculatory perfusion disturbances by exploring therapeutic approaches with different prime fluid strategies, by acting on COP (part I) and free hemoglobin scavenging with human albumin (part II). In part I, patients undergoing elective coronary artery bypass graft (CABG) surgery with cardiopulmonary bypass will be randomized in three groups receiving different prime fluid strategies. The study endpoint is the reduction in functional capillary density during the perioperative period. Sublingual microcirculatory measurements and blood sampling will take place after induction of anesthesia, during and after surgery to determine microcirculatory perfusion and parameters for hemodilution, hemolysis, COP, markers for endothelial damage and glycocalyx shedding. Measurements start on the day of surgery and end one day after surgery. In part II, participants will be randomized in two groups receiving the first dose directly after aortic cross clamping and blood cardioplegia administration, and the second dose after the third blood cardioplegia administration (± 30 min after the first dose).The most optimal prime fluid in order to preserve microcirculatory perfusion from study one, will be used as prime fluid in the second study. Microcirculatory perfusion parameters will be measured at time points comparable with study one. Blood samples are taken to determine markers for hemodilution, hemolysis, COP and endothelial damage and glycocalyx shedding. For part II see trial registration: PRIME, part II.

Interventions

COMBINATION_PRODUCTA: gelofusine + ringers

750 milliliter (mL) modified fluid gelatin (Braun Melsungen, Germany), 650 mL Ringer's solution (Baxter, Utrecht, Netherlands) and 100 mL mannitol (15%, Baxter, Utrecht, Netherlands)

COMBINATION_PRODUCTB: albumine + ringers

200 mL human albumin (20%, Sanquin, Amsterdam, Netherlands), 1200 mL Ringer's solution (Baxter, Utrecht, Netherlands) and 100 mL mannitol (15%, Baxter, Utrecht, Netherlands)

COMBINATION_PRODUCTC: ringers + retrograde autologous priming

1400 mL Ringer's solution (Baxter, Utrecht, Netherlands) and 100 mL mannitol (15%, Baxter, Utrecht, Netherlands) with retrograde autologous priming. Retrograde autologous priming (RAP) is applied using clinical parameters such as Central Venous Pressure, Mean Arterial Pressure (MAP), and intra cardiac filling pressure based on Trans Esophageal Echo as guidance to the amount of fluid displaced. RAP is applied to a maximum volume of 475 mL provided that systolic blood pressure will remain \>90 millimeter of mercury (mmHg). Phenylephrine can be administered up to 200 mcg to keep the system hemodynamics stable during RAP. In case of a body surface area \<1.7m2, a maximum volume of 375 mL is desired. Once the desired amount of prime is displaced, the transfusion bag is clamped and CPB is started. If additional fluids are needed during CPB to maintain optimal perfusion, the displaced prime is used prior to the vasoplegia protocol.

Sponsors

Amsterdam UMC, location VUmc
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Masking description

Double blind

Intervention model description

In two consecutive randomized controlled trials, the investigators study the effect of prime fluid strategies on perfused vessel density (part I) and the effect of additional albumin during cardiopulmonary bypass compared with ringers on perfused vessel density (part II). In this study part (I), the effect of prime fluid strategies on perfused vessel density. A single centre, double-blind randomized trial

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adult subjects * Informed consent * Elective coronary artery bypass surgery with cardiopulmonary bypass

Exclusion criteria

* Emergency operations * Re-operation * Elective thoracic aortic surgery * Elective valve surgery * The use of crystalloid cardioplegia * Combined procedure CABG and valve surgery * Known allergy for human albumin or gelofusine

Design outcomes

Primary

MeasureTime frameDescription
Perfused vessel density (PVD, mm mm-²)T1: within 5-10 minutes after induction of anesthesiareflecting microcirculatory diffusion capacity

Secondary

MeasureTime frameDescription
albumin (g L-¹)T1, 5-10 min after induction of anesthesia; T2, 5-10 min after aortic cross clamping; T3, 5-10 min after weaning from cardiopulmonary bypass; T4, 15-30 min after arrival on the intensive care unit; T5, 24 hours after arrival on the intensive care unit.concentration of albumin in plasma
hemolysis index (H-index)T1, 5-10 min after induction of anesthesia; T2, 5-10 min after aortic cross clamping; T3, 5-10 min after weaning from cardiopulmonary bypass; T4, 15-30 min after arrival on the intensive care unit; T5, 24 hours after arrival on the intensive care unit.the grade of hemolysis in plasma
haptoglobin (g L-¹)T1, 5-10 min after induction of anesthesia; T2, 5-10 min after aortic cross clamping; T3, 5-10 min after weaning from cardiopulmonary bypass; T4, 15-30 min after arrival on the intensive care unit; T5, 24 hours after arrival on the intensive care unit.concentration of haptoglobin in plasma
syndecan-1 (ng/ml)T1, 5-10 min after induction of anesthesia; T3, 5-10 min after weaning from cardiopulmonary bypass; T4, 15-30 min after arrival on the intensive care unit; T5, 24 hours after arrival on the intensive care unit.Concentration of syndecan-1 in plasma
heparan sulphate (ng/ml)T1, 5-10 min after induction of anesthesia; T3, 5-10 min after weaning from cardiopulmonary bypass; T4, 15-30 min after arrival on the intensive care unit; T5, 24 hours after arrival on the intensive care unit.concentration of heparan sulphate in plasma
hemoglobin (Hb, mmol L-¹)T1, 5-10 min after induction of anesthesia; T2, 5-10 min after aortic cross clamping; T3, 5-10 min after weaning from cardiopulmonary bypass; T4, 15-30 min after arrival on the intensive care unit; T5, 24 hours after arrival on the intensive care unit.concentration of hemoglobin in serum
hematocrit (Ht, L L-¹)T1, 5-10 min after induction of anesthesia; T2, 5-10 min after aortic cross clamping; T3, 5-10 min after weaning from cardiopulmonary bypass; T4, 15-30 min after arrival on the intensive care unit; T5, 24 hours after arrival on the intensive care unit.hematocrit in serum
perioperative use of packed red blood cells (PRBCs, mL)Intraoperative during cardiac surgery, postoperative period up to 24 hours postoperativeamount of packed red blood cells
fluid balance (mL)Intraoperative during cardiac surgery, postoperative period up to 24 hours postoperativefluid balance
fluid requirements (mL)Intraoperative during cardiac surgery, postoperative period up to 24 hours postoperativeAmount of fluids required
Total vessel density (TVD, mm mm-²)T1, 5-10 min after induction of anesthesia; T2, 5-10 min after aortic cross clamping; T3, 5-10 min after weaning from cardiopulmonary bypass; T4, 15-30 min after arrival on the intensive care unit; T5, 24 hours after arrival on the intensive care unit.density of capillaries reflecting the functional state of the microcirculatory diffusion capacity
Colloid oncotic pressure (COP, mmHg)T1, 5-10 min after induction of anesthesia; T2, 5-10 min after aortic cross clamping; T3, 5-10 min after weaning from cardiopulmonary bypass; T4, 15-30 min after arrival on the intensive care unit; T5, 24 hours after arrival on the intensive care unit.colloid oncotic pressure in plasma
Heterogeneity indexT1, 5-10 min after induction of anesthesia; T2, 5-10 min after aortic cross clamping; T3, 5-10 min after weaning from cardiopulmonary bypass; T4, 15-30 min after arrival on the intensive care unit; T5, 24 hours after arrival on the intensive care unit.reflecting the aspect of heterogeneity of microcirculatory perfusion
Thrombomodulin (ng mL-¹)T1, 5-10 min after induction of anesthesia; T3, 5-10 min after weaning from cardiopulmonary bypass; T4, 15-30 min after arrival on the intensive care unit; T5, 24 hours after arrival on the intensive care unit.Thrombomodulin concentration in plasma
Angiopoietin-2 (ng mL-¹)T1, 5-10 min after induction of anesthesia; T3, 5-10 min after weaning from cardiopulmonary bypass; T4, 15-30 min after arrival on the intensive care unit; T5, 24 hours after arrival on the intensive care unit.Angiopoietin-2 concentration in plasma
Interleukin-6 (ng mL-¹)T1, 5-10 min after induction of anesthesia; T3, 5-10 min after weaning from cardiopulmonary bypass; T4, 15-30 min after arrival on the intensive care unit; T5, 24 hours after arrival on the intensive care unit.Interleukin-6 concentration in plasma
Tumor necrosis factor (TNF-alpha, ng mL-¹)T1, 5-10 min after induction of anesthesia; T3, 5-10 min after weaning from cardiopulmonary bypass; T4, 15-30 min after arrival on the intensive care unit; T5, 24 hours after arrival on the intensive care unit.TNF-alpha concentration in plasma
Neutrophil gelatinase associated lipocalin (NGAL, ng mL-¹)T1, 5-10 min after induction of anesthesia; T3, 5-10 min after weaning from cardiopulmonary bypass; T4, 15-30 min after arrival on the intensive care unit; T5, 24 hours after arrival on the intensive care unit.NGAL concentration in plasma
Magnesium (mmol L-¹)T1, 5-10 min after induction of anesthesia; T2, 5-10 min after aortic cross clamping; T3, 5-10 min after weaning from cardiopulmonary bypass; T4, 15-30 min after arrival on the intensive care unit; T5, 24 hours after arrival on the intensive care unit.Magnesium concentration in plasma
Phosphate (mmol L-¹)T1, 5-10 min after induction of anesthesia; T2, 5-10 min after aortic cross clamping; T3, 5-10 min after weaning from cardiopulmonary bypass; T4, 15-30 min after arrival on the intensive care unit; T5, 24 hours after arrival on the intensive care unit.Phosphate concentration in plasma
Oxygen delivery (mL min-¹)During cardiopulmonary bypassOxygen delivery
Microvascular Flow IndexT1, 5-10 min after induction of anesthesia; T2, 5-10 min after aortic cross clamping; T3, 5-10 min after weaning from cardiopulmonary bypass; T4, 15-30 min after arrival on the intensive care unit; T5, 24 hours after arrival on the intensive care unit.Microvascular Flow Index, semi-quantitative assessment of the average red blood cell velocity per quadrant
De Backer-scoreT1, 5-10 min after induction of anesthesia; T2, 5-10 min after aortic cross clamping; T3, 5-10 min after weaning from cardiopulmonary bypass; T4, 15-30 min after arrival on the intensive care unit; T5, 24 hours after arrival on the intensive care unit.De Backer-score, proxy of total vessel density
Proportion of perfused vessels (PPV, %)T1, 5-10 min after induction of anesthesia; T2, 5-10 min after aortic cross clamping; T3, 5-10 min after weaning from cardiopulmonary bypass; T4, 15-30 min after arrival on the intensive care unit; T5, 24 hours after arrival on the intensive care unit.reflecting the aspect of heterogeneity of microcirculatory perfusion

Other

MeasureTime frameDescription
Duration of mechanical ventilation (hours)Postoperative until 30 days postoperativeDuration of mechanical ventilation (hours)
ICU stay (hours)Postoperative until 30 days postoperativeICU stay (hours)
Hospital stay (days)Postoperative until 30 days postoperativeDays until hospital discharge (days)
Acute Kidney injury (AKI)Postoperative until 30 days postoperativeAcute kidney injury (yes/no)
Respiratory failurePostoperative until 30 days postoperativeRespiratory failure (yes/no)
PneumoniaPostoperative until 30 days postoperativePneumonia (yes/no)
non-preexisting atrial fibrillationPostoperative until 30 days postoperativenon-preexisting atrial fibrillation (yes/no)
re-do surgeryPostoperative until 30 days postoperativere-do surgery (yes/no)
Extra corporeal membrane oxygenation (ECMO)Postoperative until 30 days postoperativeExtra corporeal membrane oxygenation (yes/no)
MortalityPostoperative until 30 days postoperativeIn-hospital mortality (yes/no)
Sodium (mmol/L)T1, 5-10 min after induction of anesthesia; T2, 5-10 min after aortic cross clamping; T3, 5-10 min after weaning from cardiopulmonary bypass; T4, 15-30 min after arrival on the intensive care unit; T5, 24 hours after arrival on the intensive care unit.Serum sodium
Potassium (mmol/L)T1, 5-10 min after induction of anesthesia; T2, 5-10 min after aortic cross clamping; T3, 5-10 min after weaning from cardiopulmonary bypass; T4, 15-30 min after arrival on the intensive care unit; T5, 24 hours after arrival on the intensive care unit.Serum potassium
Calcium (mmol/L)T1, 5-10 min after induction of anesthesia; T2, 5-10 min after aortic cross clamping; T3, 5-10 min after weaning from cardiopulmonary bypass; T4, 15-30 min after arrival on the intensive care unit; T5, 24 hours after arrival on the intensive care unit.Serum calcium
Chloride (mmol/L)T1, 5-10 min after induction of anesthesia; T2, 5-10 min after aortic cross clamping; T3, 5-10 min after weaning from cardiopulmonary bypass; T4, 15-30 min after arrival on the intensive care unit; T5, 24 hours after arrival on the intensive care unit.Serum chloride
Bicarbonate (mmol/L)T1, 5-10 min after induction of anesthesia; T2, 5-10 min after aortic cross clamping; T3, 5-10 min after weaning from cardiopulmonary bypass; T4, 15-30 min after arrival on the intensive care unit; T5, 24 hours after arrival on the intensive care unit.Serum bicarbonate
CO2 (kPa)T1, 5-10 min after induction of anesthesia; T2, 5-10 min after aortic cross clamping; T3, 5-10 min after weaning from cardiopulmonary bypass; T4, 15-30 min after arrival on the intensive care unit; T5, 24 hours after arrival on the intensive care unit.Carbon dioxide pressure in plasma
O2 (kPa)T1, 5-10 min after induction of anesthesia; T2, 5-10 min after aortic cross clamping; T3, 5-10 min after weaning from cardiopulmonary bypass; T4, 15-30 min after arrival on the intensive care unit; T5, 24 hours after arrival on the intensive care unit.Oxygen pressure in plasma
Activated Clotting Time (ACT, min)intraoperativeACT in minutes
pHT1, 5-10 min after induction of anesthesia; T2, 5-10 min after aortic cross clamping; T3, 5-10 min after weaning from cardiopulmonary bypass; T4, 15-30 min after arrival on the intensive care unit; T5, 24 hours after arrival on the intensive care unit.Measurement of hydrogen ions in plasma
Temperature (celsius)T1, 5-10 min after induction of anesthesia; T2, 5-10 min after aortic cross clamping; T3, 5-10 min after weaning from cardiopulmonary bypass; T4, 15-30 min after arrival on the intensive care unit; T5, 24 hours after arrival on the intensive care unit.Temperature in celsius
AgePreoperativeAge in years
GenderPreoperativeGender (male/female)
Body Surface Area (BSA)PreoperativeBSA in m2
SmokingPreoperativeMedical history of smoking (yes/no)
Diabetes on medicationPreoperativeMedical history of diabetes on medication (yes/no)
ComorbiditiesPreoperativeOther comorbidities in medical history (yes/no)
EuroSCORE IIPreoperativeThe European System for Cardiac Operative Risk Evaluation (EuroSCORE) II predicts risk of in-hospital mortality after cardiac surgery.
CPB time (min)intraoperativeCardiopulmonary bypass time in minutes
Aortic cross clamping time (AoX time, min)intraoperativeAortic cross clamping time in minutes
heparin (IU)intraoperativeDosing of heparin in international units
protamin (mg)intraoperativedosing of protamin
Oxygen saturation (Sat, %)T1, 5-10 min after induction of anesthesia; T2, 5-10 min after aortic cross clamping; T3, 5-10 min after weaning from cardiopulmonary bypass; T4, 15-30 min after arrival on the intensive care unit; T5, 24 hours after arrival on the intensive care unit.Oxygen saturation in %
Urine production (ml)T1, 5-10 min after induction of anesthesia; T2, 5-10 min after aortic cross clamping; T3, 5-10 min after weaning from cardiopulmonary bypass; T4, 15-30 min after arrival on the intensive care unit; T5, 24 hours after arrival on the intensive care unit.Urine production
Blood pressure (mmHg)T1, 5-10 min after induction of anesthesia; T2, 5-10 min after aortic cross clamping; T3, 5-10 min after weaning from cardiopulmonary bypass; T4, 15-30 min after arrival on the intensive care unit; T5, 24 hours after arrival on the intensive care unit.Blood pressure (mmHg)
Noradrenaline infusionT1, 5-10 min after induction of anesthesia; T2, 5-10 min after aortic cross clamping; T3, 5-10 min after weaning from cardiopulmonary bypass; T4, 15-30 min after arrival on the intensive care unit; T5, 24 hours after arrival on the intensive care unit.Noradrenaline infusion (mcg/kg/min)
PhenylephrineT1, 5-10 min after induction of anesthesia; T2, 5-10 min after aortic cross clamping; T3, 5-10 min after weaning from cardiopulmonary bypass; T4, 15-30 min after arrival on the intensive care unit; T5, 24 hours after arrival on the intensive care unit.Phenylephrine (mcg)
Vasopressin (IU/min)T1, 5-10 min after induction of anesthesia; T2, 5-10 min after aortic cross clamping; T3, 5-10 min after weaning from cardiopulmonary bypass; T4, 15-30 min after arrival on the intensive care unit; T5, 24 hours after arrival on the intensive care unit.Vasopressin (IU/min)
Methylene Blue (mg)T1, 5-10 min after induction of anesthesia; T2, 5-10 min after aortic cross clamping; T3, 5-10 min after weaning from cardiopulmonary bypass; T4, 15-30 min after arrival on the intensive care unit; T5, 24 hours after arrival on the intensive care unit.Methylene blue (mg)
Lactate (mmol/L)T1, 5-10 min after induction of anesthesia; T4, 15-30 min after arrival on the intensive care unit; T5, 24 hours after arrival on the intensive care unit.Serum lactate
Creatinin levels (umol/L)T1, 5-10 min after induction of anesthesia; T4, 15-30 min after arrival on the intensive care unit; T5, 24 hours after arrival on the intensive care unit.serum creatinin level
estimated glomerular filtration rate (eGFR, ml/min/1,73 m2)T1, 5-10 min after induction of anesthesia; T4, 15-30 min after arrival on the intensive care unit; T5, 24 hours after arrival on the intensive care unit.estimated glomerular filtration rate
Blood product useIntraoperative and up to 24 hours postoperativeBlood product use (ml)
Blood loss (ml)T4, 15-30 min after arrival on the intensive care unit; T5, 24 hours after arrival on the intensive care unitBlood loss

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 6, 2026